Labtest LLC

Labtest LLC was paid $4.17M by Medicaid between Jan 2018 and Oct 2023, across 80 billing codes. Its largest line is G0483, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed — 37% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Missouri

Rank by total paid#5 of 61

Median peer was paid$85K

This provider vs. median49×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	29,719	$1.68M
2019	32,587	$1.23M
2020	40,033	$795K
2021	9,265	$142K
2022	13,029	$121K
2023	14,137	$205K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	37%	9,438	7,731	$1.54M
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	21%	7,861	3,207	$892K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	9.7%	6,759	5,170	$403K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	8.4%	8,769	6,460	$349K
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	4.0%	1,599	1,226	$165K
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	2.1%	1,449	1,128	$89K
84443	Thyroid stimulating hormone (TSH)	1.9%	7,209	6,218	$81K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	1.8%	4,287	3,791	$75K
80053	Comprehensive metabolic panel	1.4%	8,192	7,067	$58K
80061	Lipid panel	1.2%	6,738	5,712	$50K
83036	Hemoglobin; glycosylated (A1C)	<1%	6,587	5,782	$40K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	8,446	6,890	$40K

68 more codes

82607		<1%	3,195	$32K
82670		<1%	1,468	$30K
84481		<1%	1,701	$21K
84146		<1%	1,458	$21K
84153		<1%	1,526	$18K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	1,248	$18K
83001		<1%	1,550	$17K
84439		<1%	2,791	$16K
84436		<1%	3,434	$14K
84403		<1%	730	$13K
82985		<1%	1,159	$13K
83525		<1%	1,401	$12K
82728		<1%	1,291	$12K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	<1%	618	$11K
86703		<1%	911	$9K
82746		<1%	929	$9K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	499	$9K
83970		<1%	337	$8K
83735		<1%	1,595	$8K
0038U		<1%	457	$6K
86431		<1%	1,484	$6K
86140		<1%	1,527	$6K
84550		<1%	1,762	$6K
82248		<1%	1,446	$5K
80048	Basic metabolic panel (calcium, ionized)	<1%	876	$5K
81225		<1%	21	$5K
84480		<1%	665	$5K
86803		<1%	521	$5K
86769		<1%	157	$4K
87340		<1%	558	$4K
83550		<1%	687	$4K
83002		<1%	701	$4K
86704		<1%	432	$3K
84681		<1%	278	$3K
84207		<1%	193	$3K
86709		<1%	437	$3K
83540		<1%	695	$3K
80069		<1%	407	$3K
85652		<1%	1,224	$2K
81001		<1%	1,040	$2K
84402		<1%	71	$2K
82570		<1%	412	$2K
36415	Collection of venous blood by venipuncture	<1%	10,613	$1K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	50	$1K
84479		<1%	538	$834.05
81003		<1%	546	$825.26
84156		<1%	409	$782.63
85018		<1%	426	$721.08
80074		<1%	29	$716.81
85014		<1%	344	$585.86
80050	General health panel	<1%	192	$443.51
80164		<1%	51	$376.67
85027		<1%	80	$361.36
84100		<1%	105	$299.41
84144		<1%	17	$197.28
82533		<1%	19	$185.90
P9603	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled	<1%	3,596	$167.03
80369		<1%	82	$152.25
85610		<1%	63	$133.77
82150		<1%	34	$129.58
80171		<1%	83	$85.63
80299		<1%	87	$77.08
85048		<1%	34	$62.49
80178		<1%	16	$59.42
80362		<1%	76	$58.14
86038		<1%	13	$55.24
87086	Culture, bacterial; quantitative colony count, urine	<1%	22	$46.77
85041		<1%	19	$42.39

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialHAIDER, SYED (CEO)

Same official

Other billing entities under HAIDER, SYED

Full network →

Provider	Location	Paid
Autism and Behavioral Spectrum LLC	Chesterfield, MO	$2.04M
Newborn and Pediatric Care of West Houston PLLC	Katy, TX	$570K
STL Diagnostic LLC	Saint Louis, MO	$320K
Cyber Diagnostic Medicine LLC	Florissant, MO	$198K
Labtest LLC	Houston, TX	$74K
Sultana's Medical, LLC	Buffalo, NY	$58K
Belleville Diagnostic Center, LLC	Belleville, IL	$2K

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.